Although localized intratumoral delivery of CD133-targeted CAR-T cells has been proposed as a strategy to mitigate this risk, clinical experience remains extremely limited, with only one study to date reporting its application in patient-derived GBM stem cells.421. The gene discussed is PROM1; the disease is glioblastoma.